TITLE

Under legal fire, Miles ends drug switch payments

AUTHOR(S)
Ukens, Carol
PUB. DATE
April 1994
SOURCE
Drug Topics;4/25/94, Vol. 138 Issue 8, p26
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the agreement between the attorneys-general of 11 states and Miles Inc. on the termination of Miles' reimbursement program that paid pharmacists for each patient agreeing to switch to Adalat CC. Features of the program; Reaction by Miles Inc.; Alleged violation of consumer protection laws.
ACCESSION #
9409141729

 

Related Articles

  • Miles takes on the Bayer name.  // Packaging Digest;Apr95, Vol. 32 Issue 5, p2 

    Reports on the changeover in labels on aspirin and other drugs hitherto marketed under the `Miles' brand to the `Bayer' trademark. Acquisition by Miles Incorporated of `Bayer' trademark from Sterling Winthrop Corporation; Changeover schedule.

  • Miles pits Bugs vs. Centrum Jr. Weisz, Pam // Brandweek;11/14/94, Vol. 35 Issue 44, p12 

    Reports on the relaunching of Miles Inc.'s Bugs Bunny line of value-priced children's chewable vitamins. Enhancements in the product; Plan for extensive sampling and couponing; Licensing deal with Sea World.

  • New one-a-day vitamins tailored to individual consumer needs. Gannon, Kathi // Drug Topics;12/13/93, Vol. 137 Issue 23, p40 

    Reports on the One-A-Day vitamin line which was revamped with new products and contemporary packaging tailored specifically for individual consumers. New products from Miles Inc.; Packaging; Consumer hotline.

  • Major campaign bolsters Bayer aspirin relaunch. Snyder, Karyn // Drug Topics;3/20/95, Vol. 139 Issue 6, p42 

    Reports on the marketing campaign launched for Bayer aspirin aimed at better communicating the product line's effectiveness to prevent disease as well as relieve pain. Advertising campaign; Miles Inc. as manufacturer of the Bayer aspirin for its parent company, Bayer AG.

  • The Post-Statin World. Trahan, Ronald C. // Pharmaceutical Executive;Apr2003, Vol. 23 Issue 4, p76 

    Comments on the need for drug marketing firms to study the possibilities in cardiovascular treatment in order to prepare drug efficacy communication strategies for therapeutic promotions. Opportunities in metabolic syndrome studies; Metrics for the diagnosis, progression and prognosis of...

  • Cerivastatin: marketing discontinued.  // WHO Drug Information;2001, Vol. 15 Issue 2, p77 

    Reports on the decision of the manufacturer of cerivastatin sodium (Baycol) to discontinue the marketing and distribution of cerivastatin in the United States. Post marketing reports of muscle weakness and rhabdomyolysis; Rare cases of rhabdomyolysis with all statins.

  • Miles sets first Dorlastan shipments.  // WWD: Women's Wear Daily;1/3/1995, Vol. 169 Issue 1, p13 

    Reports on the first shipments of the Dorlastan spandex from Miles Inc.'s Bushy Park, South Carolina facility.

  • BAYER ASSETS. Taylor, Kathryn S. // H&HN: Hospitals & Health Networks;4/5/95, Vol. 69 Issue 7, p76 

    Reports on the sale of Sterling Winthrop's over-the-counter medicine business by Miles Incorporated, a subsidiary of Bayer AG of Germany. History of the use of `Bayer' as trademane for aspirin marketed in the United States; Launching by Bayer AG of a marketing campaign to make consumers aware...

  • Borden adds formaldehyde to feed Miles isocyanates. Wood, Andrew // Chemical Week;5/18/1994, Vol. 154 Issue 19, p12 

    Reports on Borden Inc.'s Packaging and Industrial Resins Group's construction of a formaldehyde plant at Baytown, Texas. Supply of the major share of the output to Miles's isocyanates manufacture; Growth of the formaldehyde market; Price per pound of formaldehyde.

Share

Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics